A Long Term Safety Study of BCX7353 in Hereditary Angioedema

    Not Recruiting
  • End date
    Feb 15, 2024
  • participants needed
  • sponsor
    BioCryst Pharmaceuticals
Updated on 26 January 2021
Clinical Trials Coordinator
Primary Contact
Study Center (2.2 mi away) Contact
+92 other location


This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Condition HEREDITARY ANGIOEDEMA, prevention & control
Treatment BCX7353
Clinical Study IdentifierNCT03472040
SponsorBioCryst Pharmaceuticals
Last Modified on26 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note